Published in

American Association for the Advancement of Science, Science, 6451(365), p. 386-392, 2019

DOI: 10.1126/science.aav3722

Yearbook of Paediatric Endocrinology, 2020

DOI: 10.1530/ey.17.15.11

Links

Tools

Export citation

Search in Google Scholar

Targeting a ceramide double bond improves insulin resistance and hepatic steatosis

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Ceramides in focus Excess calorie intake can ultimately lead to a metabolic syndrome that interferes with fat or lipid metabolism. There are many different types of lipids, and it has been widely debated which are the true culprits underlying metabolic disorders. Chaurasia et al. report that ceramides are the major contributor to insulin resistance and fatty liver disease (see the Perspective by Kusminski and Scherer). This appears to be caused by the enzyme dihydroceramide desaturase 1 (DES1), which is normally involved in ceramide production by inserting a double bond into the backbone of the molecule. In mice fed a high-fat diet, deletion of DES1 improved glucose and lipid metabolism. Science , this issue p. 386 ; see also p. 319